SCHEMBL263758

SCHEMBL263758

COC(=O)c1ccc2ncn(CC(=O)N3CCCC3)c(=O)c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
POLB P06746 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
NPSR1 Q6W5P4 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
KMT2A Q03164 1/20 0.49
MAPK1 P28482 1/20 0.47
MMP13 P45452 2/20 0.47
LDHA P00338 1/20 0.47
LMNA P02545 2/20 0.47
HPGD P15428 2/20 0.47
KDM4E B2RXH2 1/20 0.47
USP2 O75604 1/20 0.47
TP53 P04637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263340 0.91 ALDH1A1 (0.52) ALDH1A1POLBSMN1; SMN2NPSR1TDP1
SCHEMBL268837 0.86 NPSR1 (0.55) ALDH1A1POLBSMN1; SMN2NPSR1TDP1
SCHEMBL278492 0.78 ALDH1A1 (0.50) ALDH1A1POLBSMN1; SMN2MAPK1MMP13
SCHEMBL268757 0.77 NPSR1 (0.55) ALDH1A1POLBSMN1; SMN2NPSR1TDP1
SCHEMBL28835027 0.76 ALDH1A1 (0.60) ALDH1A1POLBNPSR1TDP1KMT2A
SCHEMBL28102731 0.76 HCRTR1 (0.53) ALDH1A1POLBSMN1; SMN2NPSR1TDP1
SCHEMBL28835021 0.75 MAPT (0.53) ALDH1A1POLBSMN1; SMN2NPSR1TDP1
SCHEMBL264077 0.75 CYP3A4 (0.55) ALDH1A1POLBSMN1; SMN2NPSR1KMT2A
SCHEMBL6296213 0.75 MMP13 (0.66) SMN1; SMN2MMP13LMNA
SCHEMBL3430045 0.70 SMN1; SMN2 (0.50) ALDH1A1POLBSMN1; SMN2NPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133998-B2 Bicyclic pyrimidine derivatives as calcium channel blockers Zalicus Pharmaceuticals, Ltd. (CA) 2012-03-13 US disclosed
US-8133998-B2 Bicyclic pyrimidine derivatives as calcium channel blockers Zalicus Pharmaceuticals, Ltd. (CA) 2012-03-13 US disclosed
US-8133998-B2 Bicyclic pyrimidine derivatives as calcium channel blockers Zalicus Pharmaceuticals, Ltd. (CA) 2012-03-13 US disclosed
WO-2008138126-A1 BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS NEUROMED PHARMACEUTICALS LTD. (CA) 2008-11-20 WO disclosed
US-20080280900-A1 BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2008-11-13 US disclosed
US-20080280900-A1 BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2008-11-13 US disclosed
US-20080280900-A1 BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280900-A1 BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CACNA1E, CACNA1G, RYR1 ALDH1A1 3805/4885POLB 2341/4885SMN1; SMN2 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.